Scarica l'app Stockscreener
23.69
5.62%
-1.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$25.10
Aprire:
$24.8
Volume 24 ore:
259.20K
Relative Volume:
0.70
Capitalizzazione di mercato:
$717.71M
Reddito:
$344.23M
Utile/perdita netta:
$-24.16M
Rapporto P/E:
-27.97
EPS:
-0.8471
Flusso di cassa netto:
$28.33M
1 W Prestazione:
-3.54%
1M Prestazione:
-8.00%
6M Prestazione:
-2.03%
1 anno Prestazione:
+11.38%
Intervallo 1D:
$23.31
$24.80
Intervallo di 1 settimana:
$23.31
$25.71
Portata 52W:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
23.69 | 744.67M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences CEO Maetzold sells $104,708 in shares By Investing.com - Investing.com Australia
Castle Biosciences (NASDAQ:CSTL) Insider Sells $90,912.20 in Stock - MarketBeat
Castle Biosciences (NASDAQ: CSTL) CEO sells 4,172 shares via trusts - Stock Titan
CSTL (Castle Biosciences Inc.) reports narrower than expected Q4 2025 loss and slight revenue growth, lifting shares modestly.Open Stock Signal Network - Cổng thông tin điện tử tỉnh Tây Ninh
Castle Biosciences to present melanoma test data at conferences By Investing.com - Investing.com India
Castle Biosciences to present melanoma test data at conferences - Investing.com
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS - Yahoo! Finance Canada
Laboratory teams drive progress in skin cancer diagnostics at Castle Biosciences - Traders Union
CSTL Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus
(CSTL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Castle Biosciences, Inc. (CSTL) Stock Analysis: A 97% Upside Potential Beckons Investors - DirectorsTalk Interviews
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 - Sahm
Castle Biosciences inks expansion at Nova Place - WPXI
Castle Biosciences inks expansion at Nova Place on North SidePittsburgh Business Times - The Business Journals
Aug EndMonth: How sensitive is Castle Biosciences Inc to inflationShare Buyback & AI Enhanced Trading Signals - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Shares Down 7%What's Next? - MarketBeat
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - Bitget
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences CEO sells shares worth $246,195 By Investing.com - Investing.com Australia
Breakouts Watch: Does Castle Biosciences Inc have declining or rising EPSEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Ideas Watch: Can Castle Biosciences Inc deliver alphaWeekly Trade Report & AI Forecasted Stock Moves - baoquankhu1.vn
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock - MarketBeat
Castle Biosciences CEO sells shares worth $246,195 - Investing.com
Castle Biosciences (CSTL) CEO pre-planned sale of 9,836 shares after option exercise - Stock Titan
Strong 2025 revenue and governance focus in Castle Biosciences (CSTL) proxy - Stock Titan
Castle Biosciences, Inc. (CSTL) stock price, news, quote and history - Yahoo Finance Singapore
Castle Biosciences, Inc. (CSTL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AI Stocks: Can Castle Biosciences Inc maintain its current growth rate2026 Highlights & Daily Price Action Insights - baoquankhu1.vn
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) - Yahoo Finance
CSTL PE Ratio & Valuation, Is CSTL Overvalued - Intellectia AI
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Castle Biosciences CEO Maetzold sells shares worth $106,598 By Investing.com - Investing.com South Africa
Castle Biosciences CEO Maetzold sells shares worth $106,598 - Investing.com
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options - Stock Titan
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs - Stock Titan
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha
(CSTL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Castle Biosciences presents melanoma test data at AAD meeting By Investing.com - Investing.com Australia
Castle Biosciences Study Shows DecisionDx-Melanoma Test Enhances Risk Prediction Within AJCC Staging System - geneonline.com
Castle Biosciences presents melanoma test data at AAD meeting - investing.com
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Newswise
Castle test splits same-stage melanoma patients by 5-year survival odds - Stock Titan
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Bitget
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL) - Stock Titan
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL) - Stock Titan
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):